In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Verónica Pulito-CuetoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0000-0002-3534-8467 Belén Atienza-MateoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0000-0001-7119-0786 Joao C Batista-LizImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0009-0002-5315-9202 Rebeca Nieto-NietoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
Clara Vaquera-IllescasImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
María Sebastián Mora-GilImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
David Iturbe-FernándezImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0000-0002-5241-266X Víctor M Mora-CuestaImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0000-0002-8161-0462 Ana Serrano-CombarroImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0009-0004-0679-3766 Sheila Izquierdo-CuervoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
Carolina Aguirre PortillaImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
José M CifriánImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
Ricardo BlancoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.ORCID 0000-0003-2344-2285 Raquel López-MejíasImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain.
Funding
Boehringer Ingelheim (Spain) CSI24/72Instituto de Investigación Marqués de Valdecilla INNVAL24/10Instituto de Investigación Marqués de Valdecilla NVAL23/02Instituto de Salud Carlos III CPII21/00004Instituto de Salud Carlos III FI22/00020
6 · The paper itselfAbstract
An early and accurate diagnosis of connective tissue diseases-related interstitial lung disease (CTD-ILD) is crucial for delaying lung fibrosis, but its unknown etiology and the limitations of clinical tools make it challenging for clinicians.
Indexed as
Connective Tissue DiseasesLung Diseases, InterstitialPlatelet-Derived Growth FactorTransforming Growth Factor beta1Transforming Growth Factor beta2AdultAgedArthritis, RheumatoidBiomarkersEarly DiagnosisFemaleHumansMaleMiddle AgedScleroderma, SystemicTransforming Growth Factor beta3BiomarkersPlatelet-Derived Growth Factorplatelet-derived growth factor ATGFB1 protein, humanTGFB2 protein, humanTransforming Growth Factor beta1Transforming Growth Factor beta2Transforming Growth Factor beta3biomarkersconnective tissue diseasesinflammatory myopathiesinterstitial lung diseaseprofibrotic genespulmonary fibrosisrheumatoid arthritissystemic sclerosis
Identifiers
PMID41226758
PMCPMC12609778
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390